Executive SummarySoviet delegation met with FDA Drugs and Biologics staff Dec. 15 to discuss drug post-marketing surveillance and evaluation as part of a two day round of courtesty meetings with FDA and top HHS officials. Delegation was headed by Vladimir Lepakhin, MD/PhD, deputy minister of the Soviet Ministry of Public Health, responsible for approving and purchasing pharmaceuticals for the USSR. He was accompanied by Vladimir Severtsev, chief of state quality control inspections of medicines and medical equipment. FDAers present included Acting Commissioner James Benson, Stuart Nightingale, CarlPeck, Gerald Meyer, Robert Temple, James Bilstad and Gerald Faich. Also present were HHS' James Mason and U.S. Pharmacopeia Director-designate Jerome Halperin.
You may also be interested in...
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.
While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.
Bioresearchers at the Centers for Disease Control and Prevention are hoping that diagnostic platforms previously used to develop tests for outbreaks of other epidemic respiratory diseases, including SARS and MERS, can be built on to develop new diagnostics to detect more cases in the current coronavirus outbreak, US infectious disease authorities say. This comes as more patients are monitored around the US for the disease, and a Chicago woman returning from China tests positive.